(Q57216501)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17576025%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

title

Gantrez AN nanoparticles as an adjuvant for oral immunotherapy with allergens (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17576025%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

0 references

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17576025%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Marta Ferrer

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17576025%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Juan M. Irache

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17576025%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

author name string

Sara Gómez

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17576025%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Beatriz San Roman

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17576025%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Maria Luisa Sanz

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17576025%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

language of work or name

English

0 references

publication date

4 June 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17576025%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17576025%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

volume

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17576025%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

issue

29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17576025%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

page(s)

5263-5271

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17576025%20AND%20SRC:MED&resulttype=core&format=json

Preventive capacity of subcutaneous immunotherapy

1 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.020

Systemic reactions from allergen immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.020

Noninjection routes for immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.020

Post-marketing surveillance study on the safety of sublingual immunotherapy in pediatric patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.020

WHO position paper on oral (sublingual) immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.020

Evaluation of Eudragit-coated chitosan microparticles as an oral immune delivery system.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.020

A three-year double-blind placebo-controlled study with specific oral immunotherapy to Dermatophagoides: evidence of safety and efficacy in paediatric patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.020

Oral immunotherapy with short ragweed extract in a novel encapsulated preparation: a double-blind study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.020

Oral immunotherapy of children with rhinoconjunctivitis due to birch pollen allergy. A double blind study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.020

High dose grass pollen tablets used for hyposensitization in hay fever patients. A one-year double blind placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.020

Safety and efficacy of oral immunotherapy with standardized cat extract

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.020

Oral administration of grass pollen to hay fever patients. An efficacy study in oral hyposensitization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.020

Oral immunotherapy in birch pollen hay fever

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.020

Efficacy and safety of oral immunotherapy with short ragweed extract

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.020

Vaccine adjuvants: current state and future trends

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.020

Generation of improved mucosal vaccines by induction of innate immunity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.020

Adjuvant activity of monophosphoryl lipid A for nasal and oral immunization with soluble or liposome-associated antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.020

Oral vaccination with subunit vaccines protects animals against aerosol infection with Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.020

ISCOM-based vaccines: the second decade.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.020

Binding and uptake of biodegradable poly-DL-lactide micro- and nanoparticles in intestinal epithelia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.020

In vivo uptake of chitosan microparticles by murine Peyer's patches: visualization studies using confocal laser scanning microscopy and immunohistochemistry.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.020

Microparticles as vaccine adjuvants and delivery systems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.020

Nanoparticles with specific bioadhesive properties to circumvent the pre-systemic degradation of fluorinated pyrimidines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.020

Influence of the surface characteristics of PVM/MA nanoparticles on their bioadhesive properties

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.020

Salmonella-like bioadhesive nanoparticles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.020

A New Method for the Extraction of R Lipopolysaccharides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.020

Quantification of the bioadhesive properties of protein-coated PVM/MA nanoparticles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.020

Development of a novel vaccine delivery system based on Gantrez nanoparticles.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.020

The effects of fexofenadine on eosinophilia and systemic anaphylaxis in mice infected with Trichinella spiralis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.020

Interleukin-10 gene transfer to the airway regulates allergic mucosal sensitization in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.020

MyD88, but not toll-like receptors 4 and 2, is required for efficient clearance of Brucella abortus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.020

Modulation of the cellular immune response after oral or subcutaneous immunization with microparticles containing Brucella ovis antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.020

Analysis of the intestinal microflora using molecular methods.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.020

Mechanisms of cross hyporesponsiveness to Toll-like receptor bacterial ligands in intestinal epithelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.020

TLR7 ligand prevents allergen-induced airway hyperresponsiveness and eosinophilia in allergic asthma by a MYD88-dependent and MK2-independent pathway.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.020

Prophylactic intranasal treatment with fragments of 1,3-beta-glucanase olive pollen allergen prevents airway inflammation in a murine model of type I allergy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.020

Influence of the route of sensitization on local and systemic immune responses in a murine model of type I allergy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.020

IFN-gamma-inducing factor (IL-18) increases allergic sensitization, serum IgE, Th2 cytokines, and airway eosinophilia in a mouse model of allergic asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.020

Comparative analyses of proteins extracted by hot saline or released spontaneously into outer membrane blebs from field strains of Brucella ovis and Brucella melitensis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.020

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2007.05.020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17576025%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

1 reference